December 3, 2013
November 6, 2013
Treg: Regulatory T Cells and T Helper Cells
Our proprietary technology platform represents a novel potential treatment option for a wide range of chronic inflammatory diseases.
We are focusing on chronic inflammatory diseases where current treatments show limited efficacy, limited tolerability and for which 30% of the patients treated develop resistance.
Ovasave® is our lead product candidate. The first in man, open label, phase I/II clinical trial for severe refractory Crohn's Disease patients has been successfully completed (link1) (link2) and showed good tolerability and a strong efficacy signal in the best dose group.
A phase IIb placebo controlled study is planned in the same patient population.
Other product candidates targeting the joint and eye antigen (type II collagen), the central nervous system antigen (myelin) and the ubiquitous Heat Shock Protein antigen (HSP60) are in early stages of development.